Etibo 250mg tablet
Prescription Required
Marketed By
samarth
Pack of
30 Tablet(s) In A Bottle
Salt Composition
Lapatinib
Storage
Keep in cold place
₹3960₹10840
63.47% Off
Inclusive of all taxes
1
Etibo 250mg tablet
Delivering To: —
Indication
breast cancer
Description
Etibo 250mg tablet is an anticancer medication prescribed b y the doctor to treat Early, Advanced or Metastatic Hormone Receptor Positive (HR+) Breast Cancer in Women often in combination with other medicine. Etibo 250mg tablet contains Lapitinib that belongs to the class of tyrosine kinase inhibitor drug class. Lapitinib slows or stops the growth and spread of cancer cells.
Dosage And Administration
The dosage of Etibo 250mg tablet should be taken orally without food, on empty stomach. Swallow the whole tablet as it is. Avoid breaking, biting, chewing and crushing of tablet to maintain its efficacy. Dosage may vary based on the treatment, its stage and pateint's overall health.
Mechanism Of Action
Etibo 250mg tablet contains Lapitinib that belongs to the class of tyrosine kinase inhibitor drug class. Lapitinib blocks the HER2 and EGFR receptors (tyrosine kinases), which slows or stops the growth and spread of cancer cells.
Faqs
Etibo 250mg tablet treats Early, Advanced or Metastatic Hormone Receptor Positive (HR+) Breast Cancer in Women often in combination with other medicine.
Yes, Etibo 250mg tablet dosage is not fixed and thus vary. It all depends on the treatment, cancer stage, extent, patient's health as well as side effects severity.
Yes, there are serious side effects of Etibo 250mg tablet, such as heart problems, liver diseases, vaginal bleeding etc.
Take Etibo 250mg tablet as soon as you remember it unless it is the time for the next dose. Do not double the dosage. Also inform your doctor about the missed dose.
Etibo 250mg tablet contains Lapitinib that belongs to the class of tyrosine kinase inhibitor drug class. Lapitinib blocks the HER2 and EGFR receptors (tyrosine kinases), which slows or stops the growth and spread of cancer cells.
References
• Nolting, M., Schneider-Merck, T., & Trepel, M. (2014). Lapatinib. Small Molecules in Oncology, 125-143.
• D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R., & Bianco, R. (2015). Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer treatment reviews, 41(10), 877-883.
• Voigtlaender, M., Schneider-Merck, T., & Trepel, M. (2018). Lapatinib. Small molecules in oncology, 19-44.
• Frankel, C., & Palmieri, F. M. (2010). Lapatinib side-effect management. Clinical journal of oncology nursing, 14(2).
Related Products
MARKETER DETAILS
samarth
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.